Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 13/20 | 1.00 |
| ▸ | BRAF | P15056 | 9/20 | 1.00 |
| ▸ | KDR | P35968 | 5/20 | 0.76 |
| ▸ | RET | P07949 | 3/20 | 0.76 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.76 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.76 |
| ▸ | ABL1 | P00519 | 2/20 | 0.76 |
| ▸ | HTR1A | P08908 | 2/20 | 0.76 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.76 |
| ▸ | KIT | P10721 | 2/20 | 0.76 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.76 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.76 |
| ▸ | FLT1 | P17948 | 2/20 | 0.76 |
| ▸ | MAOA | P21397 | 2/20 | 0.76 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.76 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.76 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.76 |
| ▸ | TTK | P33981 | 2/20 | 0.76 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3545392 | 0.95 | RAF1 (0.90) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL3545281 | 0.92 | RAF1 (1.00) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL3776565 | 0.91 | RAF1 (0.84) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL3539374 | 0.91 | RAF1 (0.83) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL3542976 | 0.90 | RAF1 (0.82) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL5635314 | 0.90 | RAF1 (0.86) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL3549790 | 0.90 | RAF1 (0.81) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL3544115 | 0.90 | RAF1 (0.81) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL3782348 | 0.90 | RAF1 (0.81) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL3539204 | 0.90 | RAF1 (0.81) | RAF1BRAFKDRRETRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652041-B2 | 4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridino-2-carboxamido: N-methyl-4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridine-2-carboxamide: Raf-kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | claimed |
| US-7652041-B2 | 4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridino-2-carboxamido: N-methyl-4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridine-2-carboxamide: Raf-kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652041-B2 | 4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridino-2-carboxamido: N-methyl-4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridine-2-carboxamide: Raf-kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652041-B2 | 4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridino-2-carboxamido: N-methyl-4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridine-2-carboxamide: Raf-kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1856053-A1 | CINNAMIDE AND HYDROCINNAMIDE DERIVATIVES WITH RAF-KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006076706-A1 | CINNAMIDE AND HYDROCINNAMIDE DERIVATIVES WITH RAF-KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060160803-A1 | Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160803-A1 | Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity | MAP3K21, HIPK4, MAP3K20 | RAF1 693/4885BRAF 794/4885KDR 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.